| KDP |
Report |
Adjusted EPS |
BEAT |
pred ~$0.54 vs. cons $0.53 |
MEDIUM |
| KDP |
Report |
Total Net Sales |
BEAT |
pred ~$7.15B vs. cons $7.05B |
MEDIUM |
| KDP |
Report |
US Coffee segment operating income growth (margin recovery) |
BEAT |
pred ~-8% vs. cons ~-15% decline |
LOW |
| KDP |
Guide |
FY2026 Adjusted EPS growth (constant currency) |
UNCHANGED |
guide ~11% cc growth vs. cons ~11% cc growth (FY2026) |
MEDIUM |
| KDP |
Guide |
FY2026 Net Sales range |
UNCHANGED |
guide ~$26.1B midpoint vs. cons ~$26.2B (FY2026) |
MEDIUM |
| KDP |
Guide |
Q3 2026 EPS growth phasing (H2 acceleration commentary) |
BETTER |
guide ~high-teens % growth vs. cons ~15% growth (Q3 2026) |
LOW |
| KDP |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| KDP |
Return |
5-day cumulative residual |
+0.3% (FADE) |
A modest EPS/sales beat with reaffirmed FY guidance likely produces an initial relief pop (stock already re-rated from ~$27 to ~$31 into the print on the Barclays upgrade and coffee-easing narrative, so much of the good news is pre-priced). Over the following days, below-the-line items (convertible preferred cost, ~$190M NCI from the Coffee JV) and lingering execution risk (vacant Global Coffee Co. CEO seat, H2-weighted margin recovery) give analysts room to trim out-period (H2/FY) EPS even after an in-line-to-slight beat, causing the initial pop to fade rather than extend. |
LOW |